Project Grant R21AG091075
- Federal Grant Award Summary Wake Forest University Health Sciences received a $2.42 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded on September 1, 2025, with a completion date of August 31, 2029. The I-HEAL (Inspiring Healthy Engagement and Learning for Vascular Dementia) initiative addresses critical gaps in clinical trial participation for vascular contributions to cognitive impairment and dementia (VCID), with...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $770,558 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded July 1, 2025, with a completion date of March 31, 2030. The grant supports research to establish connections between Alzheimer's disease (AD)-related genomic markers and neuroimaging phenotypes to determine the heterogeneity of AD subtypes and their association with dementia onset. The research...
- Federal Project Grant Award Summary Wake Forest University Health Sciences received a $6.42 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded on September 15, 2025, with a completion date of September 14, 2029. This longitudinal research initiative investigates how Mediterranean and Western diet compositions affect cognitive function and biomarkers of Alzheimer's disease risk, neuroinflammation, and neurodegeneration in...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $428,410 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) on September 20, 2025, with a completion date of May 31, 2030. The award funds the Research and Education in Alzheimer's Disease and Dementias Initiative for Equity (READDIE) program, a postbaccalaureate training initiative designed to prepare scholars for entry into and completion of doctoral programs in...
- Federal Project Grant Award Summary Duke University's Office of Research Administration is executing a scientific research project funded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The $715,801 project grant, awarded June 1, 2025, with completion scheduled for March 31, 2030, supports biomedical research investigating the mechanisms linking hypertension and aging to postoperative delirium and subsequent Alzheimer's disease and related dementias...
- This Project Grant award of $599,623 from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective February 1, 2026 through January 31, 2031, funds biomedical research conducted by Wake Forest University Health Sciences to investigate the synergistic effects of unacylated ghrelin (UNAG) and endurance exercise (EE) on sarcopenia and mobility loss in aging populations. The research addresses a critical gap in gerontological science by examining how the...
- Federal Grant Award Summary Panorama Research Incorporated received a $354,000 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), with an award date of September 20, 2025, and completion date of September 19, 2026. The company will develop novel therapeutic formulations of Isthmin 1 (ISM1), an adipokine designed to address sarcopenia—age-related loss of skeletal muscle mass, strength, and quality. The research will generate...
- Federal Grant Award Summary The Buck Institute for Research on Aging received $809,486 in Project Grant funding from the National Institute on Aging (CFDA 93.866 – Aging Research program) beginning February 1, 2026, through January 31, 2031. The award supports comprehensive biomedical research investigating the role of oxidation resistance 1 (OXR1) and retromer proteins in brain aging and Alzheimer's disease and related dementias (ADRD). The research leverages multiple model systems, including...
- Federal Grant Award Summary Fred Hutchinson Cancer Center received a $2.59 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with completion targeted for August 31, 2029. The grant funds fundamental research to elucidate mechanisms of adipocyte-brain communication and their impact on glial function, neuroprotection, and brain aging, with potential implications for preventing dementia and age-related...
- Federal Project Grant Award Summary The National Institute on Aging awarded The Washington University a $2.63 million Project Grant under the Aging Research program (CFDA 93.866) beginning September 1, 2025, with completion scheduled for August 31, 2029. This research initiative investigates age-related deficits in episodic memory for both content and structure of naturalistic events, with the objective of improving early detection of cognitive decline in at-risk older adults before...
Wake Forest University Health Sciences received a $426,250 Project Grant award from the National Institute on Aging (Aging Research program, CFDA 93.866) beginning February 1, 2026, with completion targeted for January 31, 2028. The award funds a randomized, double-blind, placebo-controlled clinical trial investigating vibegron (a beta-3 adrenergic receptor agonist) as a potential treatment for multisystem functional decline associated with aging and obesity. The 12-week trial will enroll 40 middle-aged and older adults (ages 45-75) with obesity to evaluate whether vibegron administration at 75 mg/day can improve energy metabolism, cardiometabolic risk factors, physical function, and cognitive outcomes compared to placebo. The research deliverables include comprehensive assessments across multiple physiological domains: bioenergetic measures (energy expenditure, core body temperature, mitochondrial function, and thermogenic protein expression); cardiometabolic outcomes (glucose and insulin indices, lipid levels, body composition, and fat distribution); and functional assessments of physical and cognitive performance. This investigation addresses a gap in aging research by examining pharmacological activation of brown adipose tissue as a mechanism to improve multiple age-related health conditions, leveraging vibegron's FDA approval status (for overactive bladder treatment) and superior selectivity and potency compared to previously studied beta-3 adrenergic receptor agonists.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $426.3k | 1/30/26 |